Systemic Sclerosis Serum
Systemic Sclerosis Serum from IRB-consented donors with clinically confirmed SSc. Suitable for SSc-specific autoantibody serology (ACA, anti-topoisomerase I, anti-RNA polymerase III), profibrotic cytokine measurement, and serum proteomic and metabolomic biomarker work. Stratification by cutaneous subset and organ involvement available.
Systemic Sclerosis Serum for Autoimmune Fibrosis Research
Sanguine’s Systemic Sclerosis Serum is collected from IRB-consented adult donors with a clinically confirmed diagnosis of systemic sclerosis (SSc) and processed under standardised SOPs to preserve circulating proteins, autoantibodies and metabolites. Serum is an acellular matrix, so these samples are intended for analyte-level work — autoantibody serology, cytokine and growth-factor measurement, and proteomic or metabolomic profiling.
Autoimmunity, Vasculopathy and Fibrosis in Systemic Sclerosis
Systemic sclerosis is an autoimmune connective tissue disease in which immune activation, microvascular injury and excessive extracellular matrix deposition converge to produce skin and internal organ fibrosis. Its serology is unusually informative: SSc-specific autoantibodies are largely mutually exclusive and each tracks with a distinct clinical phenotype, which makes serum one of the most directly useful matrices in the disease.
- Anti-centromere antibodies (ACA), anti-topoisomerase I (anti-Scl-70) and anti-RNA polymerase III are the best-established SSc-specific autoantibodies and are measurable directly in serum.
- Autoantibody subset supports organ-risk stratification — ACA is associated with limited cutaneous disease and pulmonary arterial hypertension, anti-topoisomerase I with diffuse disease and interstitial lung disease, and anti-RNA polymerase III with rapidly progressive skin thickening and scleroderma renal crisis.
- Profibrotic mediators including TGF-beta pathway components, connective tissue growth factor (CTGF/CCN2) and IL-6 circulate in SSc and are accessible to immunoassay and multiplex panels.
- Vasculopathy is a defining feature rather than a complication; endothelial activation markers, angiogenic and anti-angiogenic factors are of particular interest in serum.
- Collagen and matrix turnover fragments provide candidate readouts of fibrotic activity independent of skin scoring.
- Serum avoids the anticoagulant additives present in plasma, which matters for some autoantibody assays, complement work and mass-spectrometry workflows.
Donor Stratification Available
- Cutaneous subset: limited cutaneous SSc vs diffuse cutaneous SSc
- Autoantibody status where documented (ACA, anti-topoisomerase I, anti-RNA polymerase III)
- Interstitial lung disease involvement
- Pulmonary arterial hypertension
- Raynaud phenomenon, digital ulceration or telangiectasia
- Treatment status: immunosuppressant, antifibrotic, vasodilator therapy, or treatment-naive
- Disease duration and modified Rodnan skin score where documented
- Matched healthy controls available
Product Features
- Research Use Only (RUO) human serum from clinically confirmed systemic sclerosis donors
- Processed under standardised SOPs and frozen to preserve labile analytes
- Rigorous donor screening and lot-level quality checks
- Standard and custom aliquot volumes; volumes reported per lot
- IRB-approved collection protocols with documented informed consent
De-identified Donor Data
- Physician-confirmed systemic sclerosis diagnosis and diagnosis method
- Demographics: age, sex assigned at birth, race/ethnicity
- Disease subset, duration and severity/stage where documented
- Donor-reported medications, allergies and comorbidities
- Optional laboratory values and clinical history on request
Applications
- SSc-specific autoantibody detection, titration and assay development
- Profibrotic cytokine and growth-factor profiling
- Serum proteomics and metabolomics in fibrotic disease
- Endothelial activation and angiogenesis analyte measurement
- Collagen and matrix turnover biomarker discovery and validation
- Antibody-phenotype correlation studies for organ-involvement risk
- Pharmacodynamic and treatment-response biomarker research
- Control and comparator material for autoimmune serology panels
Other Systemic Sclerosis Specimen Types
- Systemic Sclerosis Plasma
- Systemic Sclerosis Whole Blood
- Systemic Sclerosis PBMC
- Systemic Sclerosis Leukopak
- Systemic Sclerosis Skin Punch Biopsy
- Limited Cutaneous Systemic Sclerosis Serum
- Diffuse Cutaneous Systemic Sclerosis Serum
Compliance and Quality Assurance
- IRB-approved collection protocols and HIPAA-compliant data handling
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Standardised collection and processing SOPs
- Documentation support available for regulatory review
Ordering & Customization
Systemic Sclerosis Serum is available in standard and custom volumes to meet your study design. For pricing, current availability, international shipments or country-specific documentation requirements, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our full serum inventory, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.